All-trans retinoic acid-induced myositis in a 36-year-old patient with acute promyelocytic leukaemia: Case report and literature review

Introduction

Acute promyelocytic leukemia (APL), which accounts for about 8% of all acute myeloid leukemias, is characterized by a translocation between chromosomes 15 and 17. This translocation involves the retinoic acid receptor alpha (RARA) gene and the promyelocytic leukemia (PML) gene resulting in the PML-RARA fusion.

One consequence of PML-RARA fusion is a blockage of leukemic cells differentiation that are arrested at the promyelocyte stage. Thus, PML-RARA fusion renders APL sensible to agents that can induce cell differentiation, such as all-trans retinoid acid (ATRA).

The introduction of ATRA changed APL treatment. Once considered the most catastrophic leukemia subtype APL is now a highly curable disease. Treatments combinations using ATRA has been associated with 80-95% remission rates.

Despite its unquestionable role in APL management, ATRA can cause important side effects. Differentiation syndrome, a relatively common ATRA complication, can induce hypotension, dyspnea, fever and can even be lethal. Other ATRA side effects include genital ulcers and vasculitis.

Here we present a rare but important complication of ATRA therapy. A 36-year-old male patient that developed myositis during his frontline therapy for APL.

Case presentation

A 36-year-old male, with no significant medical history aside from nephrolithiasis, presented headaches fatigue, petechial rash and hematomas for the past 30 days and was admitted for investigation. Laboratory evaluation demonstrated a hemogloblin of 8.3 g/dl, platelets count of 41 × 10⁹/l and leucocytes of 5.2 × 10⁹/L of which approximately 30% were circulating promyelocyte with auer rods. Coagulation studies showed an international normalized ratio (INR) of 1.65, activated partial thromboplastin time (aPTT) of 23 seconds and fibrinogen of 77 mg/dL. He promptly received ATRA (45 mg/m² orally per day fractionated into 2 doses) and supportive care that included cryoprecipitate and platelet transfusions. On the following day a bone marrow aspiration was made showing 84% of promyelocytes, karyotype reveled 15;17 translocation in 4 metaphases (47, X+8[7]/47,idem, t(15;17)[4]/46xy[9]) and fluorescent in situ hybridization test detected PML-RARA fusion.

Along with ATRA the patient received 4 doses of idarubicin 12 mg/m² on days 3, 5, 7 and 9 days, levofloxacin and fluconazole as antimicrobial prophylaxis.

His treatment course was uneventful until day 9 when he presented with the onset of a fever (axillary temperature of 38.8°C) with no others complaints. There was no weight gain, edema, dyspnea, skin rashes or any other signs or symptoms suggestive of differentiation syndrome.

Broad-spectrum antibiotics were started but he remains febrile despite the treatment. Central and peripheral blood cultures were drawn every 48 hours. Urine culture were ordered despite the lack urinary tract symptoms. Contrast-enhanced sinus-chest-abdomen-pelvis computed tomography and galactomannan assays were done. No bacterial or fungal infections were identified. He also underwent transthoracic echocardiography with no evidence of a vegetation indicative of infective endocarditis. Levels of C reactive protein (CRP) rose rapidly since the onset of the fever. Achieving a peak of 17.63 mg/dl (laboratory reference < 0.5 mg/dL) on day 13.

On day 14 he developed a moderate burning sensation while eating. Oral cavity examination showed necrotic ulcers in gingival mucosa. The oral medicine team was contacted and photobiomodulation therapy was performed. By day 20 his pain was gone, the aspect of the oral cavity was better and CRP levels dropped, yet his fever persisted.

Despite the high temperature his clinical condition was excellent until day 24 when he complained of severe pain in his right calf. Physical examination showed redness, swelling, tenderness and pitting edema. No abnormalities were seen in his left leg. Our main hypothesis at the time, deep vein thrombosis, was ruled out with a negative lower limb doppler ultrasound. Creatine phosphokinase levels (CPK) were within normal ranges: 178 U/L (laboratory reference 39-308 U/L). CPK and CRP levels during his admission can be seen in Figure 1.

Figure 1
Curves showing the C reactive protein and Creatine phosphokinase levels during patient's admission.

On day 25 his calf pain got worse and CRP levels once more rose, he developed renal dysfunction, hypotension and was transferred to the intensive care unit (ICU). Just before ICU admission a magnetic resonance imaging (MRI) of his right leg was done showing an important volumetric increase in medial and lateral gastrocnemius and mild edema. The findings were suggestive of myositis. We hypothesized that it was an ATRA side-effect.

Consulting the medical literature, we observed that ATRA related myositis was managed in the same way as differentiation syndrome, so on day 26 ATRA was discontinued and therapy with intravenous dexamethasone (10 mg every 12 hours) was started. On the following day his clinical condition improved dramatically; he become afebrile, his renal function got better, his calf redness and swelling were less pronounced and CRP levels dropped. On day 29, 3 days after ATRA withdrawal, the pain had completely gone and all inflammatory signs of his calf had disappeared.

On day 30 ATRA was restarted at usual dose (45 mg/m² per day). On day 31 he left the ICU and on day 32, as there was no sign of myositis recurrence, there dexamethasone was discontinued without tapering. On day 34 we repeated the MRI with evident improvement in the myositis (Figure 2). A bone marrow aspirate was done showing morphologic and molecular remission. Patient was discharged from hospital on day 35.

Figure 2
Axial view of lower extremity T1-weighted magnetic resonance imaging (MRI), before (A) and after (B) all-trans retinoid acid withdrawal and dexamethasone therapy. Edema (red arrow) seen in the first MRI (A) can no longer be seen in the second one (B).

ATRA was again used in his consolidation treatment which started 3 weeks after hospital dismissal. At the time of this writing, he is receiving maintenance with 6-mercaptopurine, methotrexate and ATRA. He remains in remission from his leukemia and did not experience myositis recurrence.

Discussion

ATRA has introduced a new era in the management of APL but unfortunately it is not free from serious complications. Here we present a rare and potentially life threatening ATRA side effect. Patient´s main events are summarized in Figure 3.

Figure 3
Timeline showing the main events.

From our literature search, we found 15 reported cases of ATRA-related myositis from 13 articles.¹-¹³ Case reports features are summarized in Table 1. Mean and median age at the onset of ATRA-related myositis (data from the 15 reported cases plus this report) was 31.7 and 31 respectively. Only 7 of the 16 patients were male.

Table 1
Patients' characteristics of reported cases of ATRA induced myositis.

Report (reference)	Age	Gender	Time to myositis (days)	Fever	Local	Image modality	CPK level raised	RCP level raised	Bilateral	Non-musculo- skeletal involvement
Miranda 1	33	M	18	Yes	Calf	USG	Yes		Yes	No
Christ 2	28	F	9	Yes	Calf				Yes	Skin + Lung
Christ 2	48	F	17	Yes	Thigh				No	Skin
Van der Vliet 3	35	F	20	Yes	Anterior tíbia	MRI	Yes		Yes	No
Van der Vliet 3	39	M	18	Yes	Calf	MRI	No		Yes	Skin
Martínez-Chamorro 4	28	F	23	No	Calf		No		Yes	No
Melinkeri 5	6	F	10	Yes	Deltoid + thigh	MRI			Yes	Skin + gum
Chan 6	27	M	16	Yes	Calf	CT	Yes		Yes	Skin
Fabbianno 7	45	M	24	Yes	Thigh	USG	Yes		Yes	Heart
Kannan 8	18	F		Yes	Calf	MRI		Yes	No	No
Oliveira 9	29	F	31	Yes	Calf	MRI	Yes		No	No
Manglani 10	5	F	7	No	Calf	MRI			No	No
Yu 11	51	F	22	Yes	Hip + Thigh	MRI	No		Yes	No
Kim 12	64	M	17	Yes	Calf	MRI	Yes	Yes	Yes	Lung
Pecker 13	15	M	28	Yes	Thigh	MRI	Yes	Yes	No	No
This report	36	M	24	Yes	Calf	MRI	No	Yes	No	No

CPK: Creatine phosphokinase; CRP: C reactive protein; M: male; F: female, CT: computed tomography; MRI: Magnetic resonance imaging; USG: ultrasound.

The mean and median time interval between ATRA introduction and myositis was 18.9 and 18 days respectively. Differentiation syndrome onset is more rapid, which has been reported in a range of 7 to 12 days after initiation of ATRA.

All patients had lower limb involvement (16 out of 16 cases) which is often bilateral (10 out of 16 cases). One case had associated deltoid involvement ⁵ and another one had associated hip involvement.¹¹

Non-musculoskeletal involvement is commonly associated with ATRA-related myositis. 4 cases reported skin involvement,²,³,⁵,⁶ 1 lung involvement,¹² 1 heart involvement ⁷ and 1 skin and lung combined involvement.² On day 14, our patient evolved with gingival necrosis, it is not clear if it was ATRA-related side effect. Gingival hyperplasia has already been reported with ATRA therapy inclusive associated with myositis.⁵ However, our patient showed improvement of oral lesions and reduction in CRP values with photobiomodulation and antibiotics even before ATRA withdrawal. Therefore, we do not believe that this manifestation was directly related to ATRA.

ATRA-induced myositis and differential syndrome have many similarities; they both occur 2 to 3 weeks after treatment, are associated with skin involvement and may cause hypotension. Maybe the pathogenesis of both syndromes are similar. ATRA is thought to induce a release of cytokines which can lead to an important inflammatory response. Inflammation is also commonly associated with ATRA-related myositis. All but 2 cases presented fever. In addition to our report, 3 other articles mentioned CRP values all of which were elevated.⁸,¹²,¹³ For that reasons it is possible to hypothesize that myositis is just a spectrum of differentiation syndrome. It is also possible that ATRA related myositis is a "localized" manifestation of differentiation syndrome. Eyes and the heart involvement, for example, have already been described as localized presentations of differentiation syndrome. In our opinion the physiopathological hallmark of myositis and differentiation syndrome are the same: ATRA-induced inflammation.

CPK levels in ATRA-related myositis are not universally elevated. In addition to our case, 3 other reports mention normal CPK levels.³,⁴,¹¹ Anyway, it is interesting to note that despite our patient's CPK levels were always within normal limits, after treatment, his CPK levels ​​dropped more than 4 times (Figure 1). Therefore, as CPK levels may not help, diagnosis of ATRA-related myosisitis relies upon clinical suspicion and is confirmed with medical imaging. We confirmed the diagnosis with MRI, but ultrasound ⁷ and computed tomography ⁶ have already been used with success.

In our opinion this case illustrates very well a rare and important ATRA-related complication which can have devastating effects if it is not rapidly treated. In our case, once myositis was recognized, inflammatory markers and organ damage responded rapidly to a short course of high-dose steroids. This highlights the importance of prompt recognition of this complication, given its potentially life-threatening course early introduction of corticosteroids and ATRA suspension is of utmost importance. Clinicians should be aware that ATRA side effects can go much further than the classical findings of differentiation syndrome.

References

• ¹ Miranda N, Oliveira P, Frade MJ, Melo J, Marques MS, Parreira A. Myositis with tretinoin. Lancet. 1994;344(8929):1096.
• ² Christ E, Linka A, Jacky E, Speich R, Marincek B, Schaffner A. Sweet's syndrome involoving the musculoskeletal system during treatment of promyelocytic leukemia with all-trans retinoic acid. Leukemia. 1996;10(4):731-4.
• ³ van Der Vliet HJ, Roberson AE, Hogan MC, Morales CE, Crader SC, Letendre L, et al. All-trans-retinoic acid-induced myositis: a description of two patients. Am J Hematol. 2000;63(2):94-8.
• ⁴ Martínez-Chamorro C, Martínez E, Gil-Fernández JJ, Alonso A, Escudero A, Fernández-Rañada JM. ATRA-induced myositis in induction therapy of acute promyelocytic leukemia. Haematologica. 2002;87(2):Ecr08.
• ⁵ Melinkeri SR, Gupta RK, Dabadghao S.A Sweet-like syndrome manifesting as gingival hyperplasia and myositis without cutaneous involvement. Ann Hematol. 2002;81(7):397-8.
• ⁶ Chan KH, Yuen SL, Joshua D.A case of all-trans retinoic acid-induced myositis in the treatment of acute promyelocytic leukaemia. Clin Lab Haematol. 2005;27(6):399-401.
• ⁷ Fabbiano F, Magrin S, Cangialosi C, Felice R, Mirto S, Pitrolo F. All-trans retinoic acid induced cardiac and skeletal myositis in induction therapy of acute promyelocytic leukaemia. Br J Haematol. 2005;129(3):444-5.
• ⁸ Kannan K, Khan HA, Jain R, Hussein SS, Dennison D. All-trans retinoic acid-induced myositis. Br J Haematol. 2005;131(5):560.
• ⁹ Oliveira AC, Domingo-Domenech E, Arnan M, Gallardo D, Puig I, Gonzalez-Barca E. All-trans retinoic acid-induced myositis in a case of acute promyelocytic leukaemia. Int J Lab Hematol. 2008;30(3):254-5.
• ¹⁰ Manglani MV, Balamurugan P. All trans retinoic acid (ATRA) induced myositis. Indian Pediatr. 2009;46(10):912-3.
• ¹¹ Yu W, Burns CM. All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis. J Clin Rheumatol. 2009;15(7):358-60.
• ¹² Kim T-Y, Maeng CH, Kim S-Y, Yoon H-J, Cho KS, Baek SK, et al. All-trans retinoic acid-induced myositis and retinoic acid syndrome in microgranular-variant acute promyelocytic leukemia. Lab Med. 2013;44(4):348-52.
• ¹³ Pecker LH, Tsai J, Angiolillo A. All-trans retinoic acid-induced inflammatory myositis in a patient with acute promyelocytic leukemia. Pediatr Radiol. 2014;44(8):1039-41.

Publication Dates

• Publication in this collection
  27 May 2024
• Date of issue
  Jan-Mar 2024

History

• Received
  6 Nov 2021
• Accepted
  13 Jan 2022
• Published
  26 Feb 2022